Calithera Biosciences, Inc. (CALA) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Calithera Biosciences, Inc. (CALA) Bundle
Whether you're an investor or analyst, this (CALA) DCF Calculator is your go-to resource for accurate valuation. Loaded with real data from Calithera Biosciences, Inc., you can adjust forecasts and observe the effects in real-time.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2018 |
AY2 2019 |
AY3 2020 |
AY4 2021 |
AY5 2022 |
FY1 2023 |
FY2 2024 |
FY3 2025 |
FY4 2026 |
FY5 2027 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 22.3 | .0 | .0 | 9.8 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | -100 | 0 | 0 | -100 | -50 | -50 | -50 | -50 | -50 |
EBITDA | -57.3 | -88.0 | -88.3 | -115.4 | -38.3 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | -257.4 | 100 | 100 | -1183.93 | 100 | 20 | 20 | 20 | 20 | 20 |
Depreciation | .5 | 1.8 | 1.9 | 1.4 | 1.4 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 2.27 | 100 | 100 | 14.71 | 100 | 63.4 | 63.4 | 63.4 | 63.4 | 63.4 |
EBIT | -57.8 | -89.9 | -90.1 | -116.9 | -39.7 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | -259.67 | 100 | 100 | -1198.64 | 100 | 20 | 20 | 20 | 20 | 20 |
Total Cash | 136.2 | 157.4 | 115.2 | 59.5 | 25.5 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 2.0 | .5 | 1.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 8.97 | 100 | 100 | 0 | 100 | 61.79 | 61.79 | 61.79 | 61.79 | 61.79 |
Inventories | -2.0 | -.5 | -1.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | -8.97 | 100 | 100 | 0 | 100 | 58.21 | 58.21 | 58.21 | 58.21 | 58.21 |
Accounts Payable | 1.2 | 2.1 | 2.0 | 3.7 | .7 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 5.6 | 100 | 100 | 37.44 | 100 | 68.61 | 68.61 | 68.61 | 68.61 | 68.61 |
Capital Expenditure | -.2 | .0 | -.1 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | -0.96162 | 100 | 100 | -1.51 | 100 | -0.49386 | -0.49386 | -0.49386 | -0.49386 | -0.49386 |
Tax Rate, % | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 |
EBITAT | -54.4 | -86.3 | -88.5 | -167.9 | -18.9 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -52.9 | -83.7 | -86.8 | -165.0 | -20.5 | -.7 | .0 | .0 | .0 | .0 |
WACC, % | 4.19 | 4.28 | 4.37 | 4.45 | 2.12 | 3.88 | 3.88 | 3.88 | 3.88 | 3.88 |
PV UFCF | ||||||||||
SUM PV UFCF | -.7 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | -24 | |||||||||
Equity Value | 23 | |||||||||
Diluted Shares Outstanding, MM | 5 | |||||||||
Equity Value Per Share | 4.62 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real CALA financials.
- Real-World Data: Historical data and forward-looking estimates (as highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe how your inputs affect Calithera’s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive CALA Data: Pre-loaded with Calithera Biosciences' historical performance metrics and future projections.
- Customizable Assumptions: Tailor growth rates, profit margins, discount rates, tax assumptions, and capital investments.
- Interactive Valuation Tool: Automatic recalculation of Net Present Value (NPV) and intrinsic value based on user-defined parameters.
- What-If Analysis: Develop various forecasting scenarios to evaluate different potential valuation results.
- Intuitive User Interface: Designed for ease of use, making it accessible for both industry experts and newcomers.
How It Works
- Step 1: Download the Excel file for Calithera Biosciences, Inc. (CALA).
- Step 2: Review Calithera's pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the results and utilize them for your investment decisions.
Why Choose This Calculator for Calithera Biosciences, Inc. (CALA)?
- Accuracy: Utilizes real Calithera financial data to ensure precise calculations.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Avoid the complexities of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate Calithera Biosciences’ valuation before making stock transactions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess future projections.
- Startup Founders: Understand the valuation processes of established biotech firms like Calithera.
- Consultants: Provide detailed valuation analyses and reports for clients in the biotech sector.
- Students and Educators: Utilize current market data to study and teach valuation principles.
What the Template Contains
- Pre-Filled DCF Model: Calithera Biosciences’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Calithera Biosciences’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.